Finshots Daily cover image

Finshots Daily

Can Nirma make the jump from suds to pills?

Feb 17, 2024
08:05
Snipd AI
Explore Nirma's unexpected entry into the pharmaceutical industry, challenges faced in diversifying from detergent to pharma, strategic shift in Indian pharma companies towards API manufacturing, Nirma's potential growth avenues in oncology APIs and CDMO business model.
Read more

Podcast summary created with Snipd AI

Quick takeaways

  • Nirma diversifies into pharma by acquiring Glenmark Life Sciences, aiming to leverage its success and market position.
  • Glenmark Life Sciences earns higher margins with a focus on chronic therapies, benefits from domestic manufacturing incentives, and has growth potential in CDMO business.

Deep dives

Nirma's foray into the pharma business

Nirma, a detergent company, has entered the pharmaceutical industry by acquiring a majority stake in Glenmark Life Sciences. Though Nirma's previous attempts to diversify into the pharma and cement industries haven't been as successful, it aims to maintain and grow Glenmark Life Sciences by leveraging its existing success and market position.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode